Purpose: To assess the effect of guipizide maleate combined with hyperbaric oxygen therapy on neurophysiological and coagulation indices in patients with heavy craniocerebral injury.Methods: The study involved a total of 80 patients with craniocerebral injuries who were admitted to The 900th Hospital of China Joint Logistic Support Force, Fuzhou, China from January 2017 to June 2021. Patients were randomly divided into study group and a control group comprising 40 patients each. The study group received guipizidine maleate combined with hyperbaric oxygen therapy while control group received hyperbaric oxygen therapy. Differences in neurophysiological and coagulation indices were recorded for the two groups after treatment.Results: Short latency somatosensory evoked potential (SLSEP) N20 wave amplitude of the study group was significantly greater than that of control group (p < 0.05). At 3 months follow-up, Glasgow outcome score (GOS), Karnofsky performance status (KPS) score, and Barthel index in the study group were significantly lower than in control group (p < 0.05). The combined incidence of complications in the study group was 5 % (2/40), which was lower than in control group, 17.50 % (7/40)Conclusion: The combination of guipizide maleate with hyperbaric oxygen has good therapeutic effect on patients with severe craniocerebral injury. It significantly improves neuro-physiological and coagulation indices, reduces the incidence of complications during treatment, and improves neurological function. However, further clinical trials are required to validate these findings
Read full abstract